GD2

Product List

Creative Biolabs is your trusted partner for anti-GD2 CAR-T therapy development. We provide a comprehensive range of products, such as anti-GD2 vectors, cells, and viral particles. Our team understands each researcher's needs and we also offer customized CAR-T cell development services tailored to your specific requirements.

Background

GD2 is known as ganglioside G2 or GRD2, which is used as a target for immunotherapy in patients with malignant melanoma and neuroblastoma. This protein is expressed on tumors of neuroectodermal origin, including human neuroblastoma and melanoma, with highly restricted expression on normal tissues. Therefore, GD2 is associated with human neuroblastoma and melanoma. GD2-targeted immunotherapy has shown promising results in clinical trials for the treatment of melanoma and neuroblastoma patients.

Associated Diseases

Human neuroblastoma

Melanoma

Neuroblastoma

Others

Anti-GD2 CAR-T Services

Anti-GD2 CAR-T In Vitro Assays

Anti-GD2 CAR-T Expression Test

The anti-GD2 CAR-T expression test is designed to monitor the expression of the anti-GD2 CAR-T receptor and its components in T cells. At Creative Biolabs, we utilize diverse detection techniques such as flow cytometry, western blotting, and QPCR to analyze CAR expression.

Fig.1 Flow cytometry analysis of cell-surface expression of anti-GD2-CAR on transduced T cells.¹

Anti-GD2 CAR-T Cytokine Release Test

Our comprehensive cytokine release test services detect a wide range of cytokines, including IL-2, TNF-α, and IFN-γ. There are several techniques available for quantifying the levels of released cytokines including ELISAs, ELISPOT, and multiplex bead array.

Fig.2 ELISA analysis of cytokine release (IFN-γ and TNF-α) in GD2 CAR-T cells co-cultured with various glioblastoma cell lines.¹

Anti-GD2 CAR-T In Vitro Cytotoxicity Assay

We provide CAR-T cytotoxicity assays that enable researchers to determine the efficiency of anti-GD2 CAR-T cells in targeting and eliminating cancer cells expressing GD2.

Fig.3 The cytotoxicity of anti-GD2 CAR-T against various glioblastoma cell lines. GD2 CAR-T cells exhibited antigen-specific cytotoxicity against GD2+ glioblastoma cells.1

Anti-GD2 CAR-T In Vivo Assays

Anti-GD2 CAR-T Cell Therapy Animal Models

We offer in vivo anti-GD2 CAR-T cell therapy testing services in animal models. Our animal models, including xenograft, humanized, syngeneic, and transgenic models, enable researchers to assess the therapeutic efficacy and safety of CAR-T cell therapies in vivo.

Fig.4 A schematic of in situ xenograft nude mouse model.²

Efficacy Test of Anti-GD2 CAR-T

Creative Biolabs provide in vivo assays to test GD2 CAR-T cell efficacy and safety. These assays allow us to evaluate the ability of CAR-T cells to target and eliminate tumor cells, providing crucial information for assessing the efficacy of GD2 CAR-T cell therapy.

Fig.5 In vivo evaluation of the antitumor activity of anti-GD2 CAR-T. The results showed that GD2 CAR-T cells specifically eliminated tumors as measured by either bioluminescence (BLI).²

Toxicity Evaluation Anti-GD2 CAR-T

Furthermore, we recognize the importance of understanding the immune response generated by the anti-GD2 CAR T cell therapy. Therefore, we offer in vivo toxicity study services. These studies help to characterize potential side effects of the anti-GD2 CAR T cell therapy.

References

1. Zhang, Guangji.; et al. "GD2 CAR-T cells in combination with Nivolumab exhibit enhanced antitumor efficacy." Translational Oncology 32 (2023): 101663.
2. Wang, Kai.; et al. "GD2-specific CAR T cells encapsulated in an injectable hydrogel control retinoblastoma and preserve vision." Nature cancer 1.10 (2020): 990-997.